InformationClinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.
Learn why

Optimise reading forHealth ProfessionalsPatients

Closed (no longer recruiting)Last updated: 17 October 2023

RAMPART: This phase III trial is trying to assess whether using a single type of immunotherapy or a combination of two types of immunotherapy will improve survival outcomes for people with renal cell carcinoma that has been surgically removed, when compared to current standard-of-care (active monitoring)An International Investigator-led Phase III Multi Arm Multi Stage Multi-centre Randomised Controlled Platform Trial of Adjuvant Therapy in Patients With Resected Primary Renal Cell Carcinoma (RCC) at High or Intermediate Risk of Relapse

Clinical summary

Summary

This trial comprises of three different arms. Participants randomly assigned to the first arm (Arm A) will be actively monitored for 1-year, in line with current standard-of-care practice in people with resected primary renal cell carcinoma (RCC) at high- or intermediate- risk of relapse. Participants randomly allocated to the second arm (Arm B) will receive durvalumab (1500mg) every 4 weeks for 1-year (up to 13 cycles). Participants randomly allocated to the third arm (Arm C) will receive durvalumab (like those in Arm B) and tremelimumab (75mg) on day 1 and week 4 visits.

Conditions

This trial is treating patients with renal cell carcinoma.

Cancer

Urinary System Cancers Urinary System

Age

People18+

Phase

III

Trial Acronym

RAMPART

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Commercial Sponsor

AstraZeneca, University College London Hospitals

Scientific Title

An International Investigator-led Phase III Multi Arm Multi Stage Multi-centre Randomised Controlled Platform Trial of Adjuvant Therapy in Patients With Resected Primary Renal Cell Carcinoma (RCC) at High or Intermediate Risk of Relapse

Eligibility

Inclusion

  • You have had a certain type of treatment or surgical procedure.
  • Your cancer has not spread to other parts of the body.

Exclusion

  • You have been diagnosed with a prior or secondary type of cancer.
  • You have certain types of non-cancer medical conditions.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.
Message

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

+ Show non-recruiting hospitals

Closed hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

Get Support

Example

Cancer Connect

Speak with someone who has cancer clinical trial experience.

Learn more

Example

Cancer Council’s cancer nurses

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.

Learn more

Example

Information for family, friends and carers

When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.

Learn more

Victorian Cancer Registry Victorian Government

The Victorian Cancer Trials Link is supported by the Victorian Government through the Victorian Cancer Agency.

RAP

Cancer Council Victoria would like to acknowledge the traditional custodians of the land on which we live and work. We would also like to pay respect to the elders past and present and extend that respect to all other Aboriginal people.